The Importance of Controlling Terminal Complement Activity and Intravascular Hemolysis in Paroxysmal Nocturnal Hemoglobinuria (PNH)
Overview
Overview
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Risitano A, Frieri C, Marano L, Urciuoli E, Sanseverino A, Nannelli C
. Massive hemolysis in paroxysmal nocturnal hemoglobinuria after switching from proximal complement inhibitor to anti-C5 therapy: A lesson not to be forgotten. Am J Hematol. 2024; 100(1):163-167.
DOI: 10.1002/ajh.27502.
View
2.
Notaro R, Luzzatto L
. Breakthrough Hemolysis in PNH with Proximal or Terminal Complement Inhibition. N Engl J Med. 2022; 387(2):160-166.
DOI: 10.1056/NEJMra2201664.
View
3.
Jang J, Kim J, Lim C, Kleinman N, Myren K, Wang A
. Impact of Lactate Dehydrogenase and Hemoglobin Levels on Clinical Outcomes in Patients With Paroxysmal Nocturnal Hemoglobinuria: Results From the National Korean PNH Registry. J Korean Med Sci. 2024; 39(8):e81.
PMC: 10911938.
DOI: 10.3346/jkms.2024.39.e81.
View
4.
Brodsky R, Lee J, Nishimura J, Szer J
. Lactate dehydrogenase versus haemoglobin: which one is the better marker in paroxysmal nocturnal haemoglobinuria?. Br J Haematol. 2021; 196(2):264-265.
DOI: 10.1111/bjh.17860.
View
5.
Hillmen P, Szer J, Weitz I, Roth A, Hochsmann B, Panse J
. Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria. N Engl J Med. 2021; 384(11):1028-1037.
DOI: 10.1056/NEJMoa2029073.
View